2,4-dimethyl-pentane-2,3-diol | 66225-53-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,4-dimethyl-pentane-2,3-diol
• 英文别名: 2,4-Dimethyl-pentan-2,3-diol；1.1-Dimethyl-2-isopropyl-aethylenglykol；α.α-Dimethyl-α'-isopropyl-aethylenglykol；2,3-Pentanediol, 2,4-dimethyl-；2,4-dimethylpentane-2,3-diol
• CAS: 66225-53-4
• 化学式: C₇H₁₆O₂
• 分子量: 132.203
• InChiKey: GCQIRPJZONARRR-UHFFFAOYSA-N

物化性质

• 熔点：
  59°C
• 沸点：
  233.16°C (rough estimate)
• 密度：
  0.9744 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2905399090

反应信息

• 作为反应物：
  描述：

  2,4-dimethyl-pentane-2,3-diol 在 硫酸 作用下， 生成 2,4-二甲基-3-戊酮
  参考文献：
  名称：

  Blaise; Herman, Annales de Chimie (Cachan, France), 1910, vol. <8>20, p. 189

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4-二甲基-2-戊烯 在 乙醚 、 硫酸 作用下， 生成 2,4-dimethyl-pentane-2,3-diol
  参考文献：
  名称：

  Hickinbottom et al., Journal of the Chemical Society, 1955, p. 1360,1362

  摘要：

  DOI：

文献信息

• Photochemical reaction of alcohols-I
  作者：R.Erra Balsells、A.R. Frasca

  DOI：10.1016/0040-4020(82)80003-3

  日期：1982.1

  The UV irradiation of aliphatic alcohols gave α-glycols as the principal products. The values of the dl-α-glycol ratios obtained in each example were analyzed.

  脂肪族醇的紫外线照射得到α-二醇作为主要产物。分析在每个实施例中获得的dl -α-二醇比率的值。
• Concentrated, stable fabric softening composition
  申请人：——

  公开号：US20030153483A1

  公开（公告）日：2003-08-14

  Principal solvents, especially mono-ol and diol principal solvents, having a ClogP of from about 0.15 to about 0.64, preferably from about 0.25 to about 0.62, and more preferably from about 0.40 to about 0.60, are disclosed that have the ability to make clear aqueous fabric softener compositions containing relatively high concentrations of fabric softener actives having ester linkages in their long, hydrophobic chains. The fabric softener actives are either unsaturated, or have intermediate length chains (˜C 12-14 ) and the said principal solvents are used at levels of less than about 40%. Other solvents may be present. Some of the said principal solvents are novel compounds and/or novel mixtures. Premixes of the fabric softening actives, the principal solvents, and, optionally, other solvents are useful in the preparation of complete formulations by obviating/limiting the need for heating.

  本发明涉及主要溶剂，特别是具有从约0.15到约0.64的ClogP值的单醇和二醇主要溶剂，优选从约0.25到约0.62，更优选从约0.40到约0.60，具有使含有长的亲水性链中的酯键的织物柔软剂活性成分相对高浓度的清澈水性织物柔软剂组合物的能力。织物柔软剂活性成分可以是不饱和的，也可以具有中等长度的链（约C12-14），所述主要溶剂的使用水平低于约40％。其他溶剂可能也存在。其中一些主要溶剂是新化合物和/或新混合物。织物柔软剂活性成分、主要溶剂和可选的其他溶剂的预混物可用于制备完整配方，从而避免/限制加热的需要。
• Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：Aicher Thomas Daniel

  公开号：US20100204240A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及本文所讨论的其他疾病和紊乱。
• Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：AICHER Thomas Daniel

  公开号：US20120277242A1

  公开（公告）日：2012-11-01

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  本发明提供了式(I)的化合物：其中R2、R3、R13、L和D2如规范中所定义，它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用，或者可以通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及其他疾病和疾病，如在此处所讨论的。
• HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US20140066424A1

  公开（公告）日：2014-03-06

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及化合物和方法，可用作HIF通路活性的抑制剂，用于治疗或预防癌症和其他缺氧介导的疾病。